China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round. The funding round was led by Jiarui Investment and Hesheng Venture Capital. The proceeds from this investment will be directed towards the research and development of the company’s cell therapy platform technology.
Expanding CDMO Services for Cell Therapy
Hillgene Bio offers comprehensive CAR-T cell CDMO solutions that support the entire spectrum from investigator-initiated trials (IIT) to IND applications, clinical trials, and commercial production levels. The company’s services encompass lentivirus CDMO supply and plasmid CDMO services, positioning it as a key player in the cell therapy sector.
Strong Financial Performance in Q1 2023
In the first quarter of 2023, Jiangsu Hillgene Biopharma Co., Ltd reported accumulated orders exceeding RMB 400 million (USD 58.9 million), with operating revenue and cash inflows reaching RMB 30 million (USD 4.36 million). This strong financial performance underscores the company’s growing market presence and the demand for its CDMO services in the cell therapy space.-Fineline Info & Tech
